Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.Zhao, H., Serby, M.D., Xin, Z., Szczepankiewicz, B.G., Liu, M., Kosogof, C., Liu, B., Nelson, L.T., Johnson, E.F., Wang, S., Pederson, T., Gum, R.J., Clampit, J.E., Haasch, D.L., Abad-Zapatero, C., Fry, E.H., Rondinone, C., Trevillyan, J.M., Sham, H.L., Liu, G.
(2006) J Med Chem 49: 4455-4458
- PubMed: 16854050
- DOI: https://doi.org/10.1021/jm060465l
- Primary Citation of Related Structures:
- PubMed Abstract:
C-Jun NH2 terminal kinases (JNKs) are important cell signaling enzymes. JNK1 plays a central role in linking obesity and insulin resistance. JNK2 and JNK3 may be involved in inflammatory and neurological disorders, respectively. Small-molecule JNK inhibitors could be valuable tools to study the therapeutic benefits of inhibiting these enzymes and as leads for potential drugs targeting JNKs. In this report, we disclose a series of potent and highly selective JNK inhibitors with good pharmacokinetic profiles.
Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6098, USA. Hongyu.email@example.com